BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19452305)

  • 1. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
    Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
    [No Abstract]   [Full Text] [Related]  

  • 2. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 3. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 5. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment.
    Rini BI; Shah SN
    Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment.
    Vaishampayan U
    Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Larkin J; Gore M
    Nat Rev Urol; 2009 Dec; 6(12):636-8. PubMed ID: 19956190
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
    Albiges L; Oudard S; Negrier S; Caty A; Gravis G; Joly F; Duclos B; Geoffrois L; Rolland F; Guillot A; Laguerre B; Legouffe E; Kohser F; Dietrich PY; Theodore CA; Escudier B
    J Clin Oncol; 2012 Feb; 30(5):482-7. PubMed ID: 22231040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    Vira MA; Novakovic KR; Pinto PA; Linehan WM
    BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract]   [Full Text] [Related]  

  • 17. [Renal cell carcinoma].
    Oya M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
    [No Abstract]   [Full Text] [Related]  

  • 18. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
    Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.